Outsourcing Outlook

Publication
Article
Pharmaceutical TechnologyPharmaceutical Technology-02-02-2002
Volume 26
Issue 2

The author discusses current economic times and conditions for large pharmaceutical companies.

External Link - article-9504.pdf

Articles in this issue
Using Earned-Value Analysis to Better Manage Projects
Microbial Bioburden on Oral Solid Dosage Forms
Overview of Technologies Supporting Security Requirements in 21 CFR Part 11, Part I
Modernizing Pharmaceutical Manufacturing
The Role of Computational Fluid Dynamics in the Pharmaceutical Industry
Available Guidance and Best Practices for Conducting Forced Degradation Studies
Outsourcing Outlook
Effect of Formulation and Process Variables on Matrix Erosion and Drug Release from a Multiunit Erosion Matrix of a Poorly Soluble Drug
Recent Videos
Jens Schmidt, associate director MSAT at Lonza
Roger Viney, PhD, chief commercial officer for ICE Pharma
Christian Dunne, director of Global Corporate Business Development at ChargePoint Technology
CPHI Milan 2024: Highlighting the Benefits of Integrated Services
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Related Content
TOP NEWS on grunge world map | Image Credit: © Sean K - © Sean K - stock.adobe.com

Samsung Biologics Scores Major Manufacturing Deal Worth Over $1.4 Billion with European Pharma Company

Feliza Mirasol
January 17th 2025
Article

Production is set to take place at Samsung Biologics’ Songdo, South Korea, site, and the agreement will run through December 2030, subject to change.

Drug Solutions Podcast: Unlocking the Latest Manufacturing Trends

Drug Solutions Podcast: Unlocking the Latest Manufacturing Trends

Felicity Thomas
July 11th 2023
Podcast

In this episode, Sergey Vlasenko from Agilent chats about bio/pharmaceutical manufacturing trends, with a particular focus on oligonucleotides.

Hand shaking which print screen on wooden cube block in front of human icon for business deal and agreement concept | Image Credit: © Dilok – © Dilok - stock.adobe.com

Lonza and Iconovo Team Up on Intranasal Biologic Candidate

Feliza Mirasol
January 15th 2025
Article

Lonza will work with Iconovo to develop spray-dried formulations for an intranasally delivered biologic using a reformulated biologic drug candidate for obesity.

Drug Solutions Podcast: Examining the State of Biopharma Investment

Drug Solutions Podcast: Examining the State of Biopharma Investment

Grant Playter
June 6th 2023
Podcast

In this episode, Siegfried Schmitt, vice president, Technical at Parexel, discusses the state of biopharma investment in 2023.

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

Argobio and University of Southern Denmark Launch New Next-Gen RNA Company, Inverna Therapeutics

Feliza Mirasol
January 8th 2025
Article

Using splicing technology, the new company aims to innovate safer and more effective RNA therapies for severe genetic diseases.

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

With New Funding, Orbis Medicines to Develop Oral Macrocycles as Alternative to Biologic Drugs

Feliza Mirasol
January 7th 2025
Article

With the new $94 million (€90 million) funding, the company will develop its pipeline of oral macrocycle drugs, nCycles, against validated biologic targets.